Enhertu Poised To Rewrite The Standard Of Care After ESMO

 
• By Jessica Merrill
  
high jump
AZ/Daiichi's Enhertu raised the bar in advanced HER2-positive breast cancer • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category